An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

Daniel Morgensztern, Nina Karaseva, Enriqueta Felip, Ignacio Delgado, Olga Burdaeva, Manuel Dómine, Primo N Lara, Paul K. Paik, Ulrik Lassen, Sergey Orlov, José Trigo, Marina Shomova, Katherine Baker-Neblett, James Vasquez, Xiaowei Wang, Li Yan, Ionel Mitrica, M. Phillip DeYoung, Pilar Garrido

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Objectives: GSK3052230 (FP-1039) is a soluble fusion protein that acts as ligand trap sequestering fibroblast growth factors (FGFs) involved in tumor growth and angiogenesis, while sparing the hormonal FGFs. Because of this selectivity, the molecule is predicted to avoid toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxicities. Herein we report the results of a phase 1b study where GSK3052330 was administered with standard of care chemotherapy in FGFR1-amplified squamous non-small cell lung cancer (sqNSCLC) patients. Methods and Methods: Eligible patients with stage IV or recurrent metastatic sqNSCLC harboring FGFR1 gene amplification received escalating doses of GSK3052230 in combination with paclitaxel and carboplatin at the starting doses 200 mg/m2 and AUC of 6, respectively, in the first line setting (Arm A) or docetaxel 75 mg/m2 in second line (Arm B). The primary endpoints of the study were safety and tolerability, to identify a maximum tolerated dose (MTD), and to assess overall response rate (ORR) based on investigator assessment. Results: Twenty-nine patients were enrolled into the study, including 20 patients on Arm A and 9 patients on Arm B. There were no dose limiting toxicities in either Arm and the MTD was not reached. The most common adverse events (AEs) were compatible with the chemotherapy backbone used in each Arm, including neutropenia, alopecia, nausea, arthralgia, asthenia, diarrhea and peripheral neuropathy. The overall response rate and median progression-free survival were 47% and 5.5 months, respectively, for Arm A and 0% and 4.6 months, respectively, for Arm B. Conclusion: GSK3052230 is a novel FGFR pathway inhibitor, which is well tolerated in combination with chemotherapy. Importantly, AEs associated with small molecule inhibitors of FGFR were not observed, as predicted by the unique mechanism of action of this drug.

Original languageEnglish (US)
Pages (from-to)74-79
Number of pages6
JournalLung Cancer
Volume136
DOIs
StatePublished - Oct 1 2019

Keywords

  • Combination therapy
  • FGFR1
  • Ligand trap
  • Phase 1
  • Squamous non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Morgensztern, D., Karaseva, N., Felip, E., Delgado, I., Burdaeva, O., Dómine, M., Lara, P. N., Paik, P. K., Lassen, U., Orlov, S., Trigo, J., Shomova, M., Baker-Neblett, K., Vasquez, J., Wang, X., Yan, L., Mitrica, I., DeYoung, M. P., & Garrido, P. (2019). An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer, 136, 74-79. https://doi.org/10.1016/j.lungcan.2019.08.011